Loading...
Market
Will Bristol Myers Squibb report increased sales of Breyanzi in Q3 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Bristol Myers Squibb Q3 2024 financial report
Story
FDA Approves Bristol Myers' Breyanzi (Liso-Cel) for Relapsed Mantle Cell Lymphoma, Third Approval This Year
May 30, 2024, 07:25 PM
The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Breyanzi, also known as Liso-Cel, a CAR T cell therapy, for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) after two lines of therapy. This approval, announced on Thursday, marks the third time this year that the FDA has expanded the use of Breyanzi for treating aggressive and rare types of blood cancer.
View original story
Similar markets
Increase in sales • 33%
Decrease in sales • 33%
No significant change • 34%
Above $500 million • 50%
Below $500 million • 50%
Profit decrease • 50%
Profit increase • 50%
